Dutch-Flemish public-private partnership aims to save money for patients and contribute to GDP growth
One month ago, the Dutch government approved the funding of an R&D project proposed by the public-private partnership RegMed XB, which works on regenerative medicine—the branch of medicine that aims to repair or replace damaged tissues.
The partnership will receive up to €56 million from the National Growth Fund to build a pilot plant for regenerative medicine therapies, such as those based on stem cells, for patients suffering from diseases including diabetes and kidney failure.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.